MedMira CEO Awarded Honorary Doctor of Science by Acadia University

HALIFAX, Aug. 21, 2013 /CNW/ - Acadia University, in Wolfville, Nova Scotia has awarded an Honorary Doctor of Science to Hermes Chan, CEO and Co-Founder of MedMira Inc.  Mr. Chan took part in the celebrations for the 100^th Anniversary of the Chemistry Department at Acadia University last week.

"On behalf of the Company's Board of Directors, I congratulate Hermes on being selected for this honor by Acadia University's Chemistry Department, where the vision for MedMira was born," said Markus Meile, Director.  "This recognition is a testament to his personal and professional accomplishments as a scientist and a business leader, the co-creator of MedMira's patented rapid diagnostic technology, and the driving force behind the Company's validation by top tier healthcare regulators and care providers around the globe."

During his time as a student in Acadia University's Chemistry Department, Mr. Chan, along with co-founder, Carlina Hui, worked together to cultivate the innovation and inspiration behind MedMira's award winning, patented rapid flow-through technology.  In 1993 they established MedMira to further develop and commercialize this technology and rapid testing solutions for HIV, Hepatitis, Syphilis, H. Pylori and other infectious diseases.  Today the Company is recognized around the world by leading healthcare providers, governments, and international organizations for its unique diagnostic platform and its high quality rapid tests which have achieved Health Canada, United States Food & Drug Administration, and China State Food and Drug Administration approvals.  The Company continues to operate in Nova Scotia, where its corporate headquarters and ISO, cGMP research and manufacturing facilities are located.

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The Company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: MEDMIRA INC.

MedMira Contact:
Andrea Young, Corporate Communications
Tel: [phone]
Email: [email protected]